[CLSTR]
< Back to situations

[ORGANIZATION]

Revolution Medicines

Featured in 13 tracked stories · first seen

Situations

[QUIET] [HEALTH] [US] [IT] [GR]

FDA approves Rasonque; EMA recommends for pancreatic cancer

44 clusters · 321 sources · last updated

Latest: Pancreatic cancer: New research and treatment developments in Greece

On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R

[QUIET] [HEALTH] [CN] [JP]

KRAS mutation cancer research and therapy development

2 clusters · 10 sources · last updated

Latest: KRAS targeted therapies face subtype efficacy challenges

Research into KRAS-targeted cancer therapies has focused on identifying the biological mechanisms behind drug resistance and the varying efficacy of treatments across different mutation subtypes. Initial studies using m

Also covered in